The treatment of Graves' disease: Current views and controversies

被引:8
作者
Orgiazzi, Jacques [1 ]
机构
[1] Univ Lyon 1, Hosp Civils Lyon, Ctr Hosp Lyon Sud, Serv Endocrinol Diabetol Malad Metab, F-69495 Pierre Benite, France
来源
PRESSE MEDICALE | 2011年 / 40卷 / 12期
关键词
ANTITHYROID DRUGS; THYROID STORM; HYPERTHYROIDISM; THERAPY; RADIOIODINE; THYROTOXICOSIS; RELAPSE; PROPYLTHIOURACIL; PREDICTORS; MANAGEMENT;
D O I
10.1016/j.lpm.2011.09.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The treatment of Graves' disease: Current views and controversies One of the more prevalent among the organ-specific autoimmune diseases, Graves' disease share their chronic evolution and lack of immunomodulatory treatment. Treatment strategy has to consider as opposite options as medical conservatory or ablative approach which requires much expertise and attention to patients' wish. Whatever treatment option, it is mandatory to prevent any risk of iatrogenic hypothyroidism, especially a rise of TSH above normal limit. The long-lasting benefit-risk ratio of treatment options is of primordial importance in this usually benign but enduring disease. Occurrence of Graves' orbitopathy, a significant complication, requires a special multidisciplinary management; the same is true in the case of a current or planned pregnancy. Overall quality-of-life is often markedly affected by Graves' disease; this should not be overlooked. Smoking increases relapse risk after a course of antithyroid drug; it also increases the risk and severity of Groves' orbitopathy. Patients must be made aware of these deleterious effects and encouraged to quit smoking.
引用
收藏
页码:1155 / 1162
页数:8
相关论文
共 31 条
  • [1] A systematic review of drug therapy for Graves' hyperthyroidism
    Abraham, P
    Avenell, A
    Park, CM
    Watson, WA
    Bevan, JS
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 153 (04) : 489 - 498
  • [2] Graves' disease:: A long-term quality-of-life follow up of patients Randomized to treatment with antithyroid drugs, radioiodine, or surgery
    Abraham-Nordling, M
    Törring, O
    Hamberger, B
    Lundell, G
    Tallstedt, L
    Calissendorff, J
    Wallin, G
    [J]. THYROID, 2005, 15 (11) : 1279 - 1286
  • [3] High dose 131I therapy for the treatment of hyperthyroidism caused by Graves' disease
    Alexander, EK
    Larsen, PR
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (03) : 1073 - 1077
  • [4] ANTITHYROID DRUGS AND GRAVES-DISEASE - A PROSPECTIVE RANDOMIZED EVALUATION OF THE EFFICACY OF TREATMENT DURATION
    ALLANNIC, H
    FAUCHET, R
    ORGIAZZI, J
    MADEC, AM
    GENETET, B
    LORCY, Y
    LEGUERRIER, AM
    DELAMBRE, C
    DERENNES, V
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (03) : 675 - 679
  • [5] Systematic review: Agranulocytosis induced by nonchemotherapy drugs
    Andersohn, Frank
    Konzen, Christine
    Garbe, Edeltraut
    [J]. ANNALS OF INTERNAL MEDICINE, 2007, 146 (09) : 657 - 665
  • [6] Bahn Rebecca S, 2009, Thyroid, V19, P673, DOI 10.1089/thy.2009.0169
  • [7] Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism
    Boelaert, K.
    Syed, A. A.
    Manji, N.
    Sheppard, M. C.
    Holder, R. L.
    Gough, S. C.
    Franklyn, J. A.
    [J]. CLINICAL ENDOCRINOLOGY, 2009, 70 (01) : 129 - 138
  • [8] Prevalence and clinical significance of antineutrophil cytoplasmic antibody in Graves' patients treated with propylthiouracil
    Cin, M. Ozduman
    Gursoy, A.
    Morris, Y.
    Aydintug, O. Tiryaki
    Kamel, N.
    Gullu, S.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (02) : 299 - 302
  • [9] PROPYLTHIOURACIL LEVELS IN HYPERTHYROID PATIENTS UNRESPONSIVE TO LARGE DOSES - EVIDENCE OF POOR PATIENT COMPLIANCE
    COOPER, DS
    [J]. ANNALS OF INTERNAL MEDICINE, 1985, 102 (03) : 328 - 331
  • [10] Drug therapy: Antithyroid drugs
    Cooper, DS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (09) : 905 - 917